Citation Impact
Citing Papers
Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia
2002
Bactericidal/permeability-increasing protein—Lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia
2001
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
2009 Standout
A Review of Antimicrobial Peptides and Their Therapeutic Potential as Anti-Infective Drugs
2005
Pediatric sepsis and multiple organ dysfunction syndrome
2001
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 Standout
The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials
2001 Standout
Drotrecogin Alfa (Activated) in Adults with Septic Shock
2012 Standout
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
2004 Standout
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Larvicidal efficacy and biological stability of a botanical natural product, zedoary oil-impregnated sand granules, against Aedes aegypti (Diptera, Culicidae)
2006
Why have clinical trials in sepsis failed?
2014
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
2008 Standout
Concept of PIRO as a new conceptual framework to understand sepsis
2005
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
2008 Standout
Progressive Statistics for Studies in Sports Medicine and Exercise Science
2008 Standout
Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery
2001
What is the real role of antimicrobial polypeptides that can mediate several other inflammatory responses?
2003
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
2010 Standout
Anti-endotoxin properties of cationic host defence peptides and proteins
2005
Designing antimicrobial peptides: form follows function
2011 Standout
International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics*
2005 Standout
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
2009 Standout
Sepsis and septic shock
2018 Standout
Myocardial depressant effects of interleukin 6 in meningococcal sepsis are regulated by p38 mitogen-activated protein kinase*
2011
Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock
2004
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
2005 Standout
Transcriptional Instability during Evolving Sepsis May Limit Biomarker Based Risk Stratification
2013
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
2010 Standout
R‐form LPS, the master key to the activation ofTLR4/MD‐2‐positive cells
2006 StandoutNobel
‘Small Changes' to Diet and Physical Activity Behaviors for Weight Management
2013 Standout
Endotoxin antagonism: conceptual basis and therapeutic potential
2002 StandoutNobel
Innate immunity of the newborn: basic mechanisms and clinical correlates
2007 Standout
Downregulation of the Drosophila Immune Response by Peptidoglycan-Recognition Proteins SC1 and SC2
2006 StandoutNobel
Emerging drugs for the treatment of sepsis
2016
Reporting of Noninferiority and Equivalence Randomized Trials
2012 Standout
Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*
2009
The immunopathology of sepsis and potential therapeutic targets
2017 Standout
Mammalian defensins in the antimicrobial immune response
2005 Standout
CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials
2011 Standout
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 Standout
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samples
2009 Standout
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
2007 Standout
Biological effects of essential oils – A review
2007 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
The Epidemiology of Severe Sepsis in Children in the United States
2003
Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration
2008 Standout
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 Standout
Receptors, Mediators, and Mechanisms Involved in Bacterial Sepsis and Septic Shock
2003
Nicotine replacement therapy for smoking cessation
2012 Standout
Invited review: Bacterial lipopolysaccharides and innate immunity
2001
Assessment of Clinical Criteria for Sepsis
2016 Standout
Peptide Antimicrobial Agents
2006 Standout
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
2016 Standout
Comparable Efficacies of the Antimicrobial Peptide Human Lactoferrin 1-11 and Gentamicin in a Chronic Methicillin-Resistant Staphylococcus aureus Osteomyelitis Model
2005
Bacterial lipopolysaccharides and innate immunity.
2001
CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials
2010 Standout
Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
2020 Standout
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
2007 Standout
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
2004 Standout
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
2001 Standout
Immunomodulatory Activities of Small Host Defense Peptides
2005
Invited review: Detoxifying endotoxin: time, place and person
2005
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Lipopolysaccharide Endotoxins
2002 Standout
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
2001 Standout
Antimicrobial proteins and peptides: anti-infective molecules of mammalian leukocytes
2004
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
2009 Standout
Anti-endotoxin properties of cationic host defence peptides and proteins
2005
Part 14: Pediatric Advanced Life Support
2010 Standout
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
2010 Standout
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
2010 Standout
Works of Sun Sook Kim being referenced
Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial
2000
Evaluation of natural products on inhibition of inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) in cultured mouse macrophage cells
2002